论文部分内容阅读
目的 观察恩替卡韦联合益气活血方治疗乙型肝炎肝硬化代偿期的临床效果;方法 选择2013G5-2015G4我院收治的乙型肝炎肝硬化代偿期患者54例作为研究对象,随机分为治疗组27例和对照组27例,分别接受恩替卡韦联合益气活血方和单用恩替卡韦治疗方案,3个月为一个疗程,两组均治疗两个疗程后比较两组患者的肝纤维化指标,乙肝病毒标志物情况及肝功能指标;结果 治疗组血清纤维化指标变化明显优于对照组,治疗组白蛋白指标升高幅度明显较对照组高,乙肝病毒DNA阴转及HBe Ag阴转两组差异无统计学意义;结论 关幼波提出的益气活血法联合恩替卡韦治疗乙型肝炎肝硬化代偿期较单用恩替卡韦能更好抗肝纤维化,阻滞肝硬化的发展.
Objective To observe the clinical efficacy of entecavir and Yiqi Huoxue Fang in the treatment of decompensated hepatitis B patients with cirrhosis.Methods 54 patients with decompensated hepatitis B cirrhosis in our hospital from 2013G5-2015G4 were selected and randomly divided into treatment group 27 cases and control group, 27 cases were entecavir combined with Yiqihuowei and entecavir alone regimen, 3 months for a course of treatment, two groups were treated for two courses after treatment compared the two groups of liver fibrosis indicators, hepatitis B virus Markers and liver function indicators. Results The changes of serum fibrosis indexes in the treatment group were significantly better than those in the control group. The increase of albumin index in the treatment group was significantly higher than that in the control group. There was no difference between the two groups Statistical significance; Conclusion of the young wave proposed by the Qi and activating blood method combined with entecavir treatment of hepatitis B cirrhosis decompensation than single use of entecavir better anti-liver fibrosis, blocking the development of cirrhosis.